1. Home
  2. CPIX vs FGEN Comparison

CPIX vs FGEN Comparison

Compare CPIX & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPIX
  • FGEN
  • Stock Information
  • Founded
  • CPIX 1999
  • FGEN 1993
  • Country
  • CPIX United States
  • FGEN United States
  • Employees
  • CPIX N/A
  • FGEN N/A
  • Industry
  • CPIX Biotechnology: Pharmaceutical Preparations
  • FGEN Biotechnology: Pharmaceutical Preparations
  • Sector
  • CPIX Health Care
  • FGEN Health Care
  • Exchange
  • CPIX Nasdaq
  • FGEN Nasdaq
  • Market Cap
  • CPIX 68.7M
  • FGEN 34.5M
  • IPO Year
  • CPIX 2009
  • FGEN 2014
  • Fundamental
  • Price
  • CPIX $4.95
  • FGEN $0.54
  • Analyst Decision
  • CPIX
  • FGEN
  • Analyst Count
  • CPIX 0
  • FGEN 0
  • Target Price
  • CPIX N/A
  • FGEN N/A
  • AVG Volume (30 Days)
  • CPIX 4.2M
  • FGEN 709.3K
  • Earning Date
  • CPIX 03-04-2025
  • FGEN 02-24-2025
  • Dividend Yield
  • CPIX N/A
  • FGEN N/A
  • EPS Growth
  • CPIX N/A
  • FGEN N/A
  • EPS
  • CPIX N/A
  • FGEN N/A
  • Revenue
  • CPIX $36,785,442.00
  • FGEN $180,015,000.00
  • Revenue This Year
  • CPIX N/A
  • FGEN $21.91
  • Revenue Next Year
  • CPIX N/A
  • FGEN N/A
  • P/E Ratio
  • CPIX N/A
  • FGEN N/A
  • Revenue Growth
  • CPIX N/A
  • FGEN 16.15
  • 52 Week Low
  • CPIX $1.04
  • FGEN $0.18
  • 52 Week High
  • CPIX $6.43
  • FGEN $2.80
  • Technical
  • Relative Strength Index (RSI)
  • CPIX 64.57
  • FGEN 54.38
  • Support Level
  • CPIX $4.12
  • FGEN $0.46
  • Resistance Level
  • CPIX $5.29
  • FGEN $0.51
  • Average True Range (ATR)
  • CPIX 0.71
  • FGEN 0.04
  • MACD
  • CPIX 0.14
  • FGEN -0.00
  • Stochastic Oscillator
  • CPIX 59.08
  • FGEN 93.75

About CPIX Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

About FGEN FibroGen Inc

FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.

Share on Social Networks: